Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors

NCT01248949 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT01248949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01248949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors
Lead sponsor
MedImmune LLC
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2010
Completion date
October 31, 2015
Enrollment
162 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced recurrent ovarian tumors, advanced solid tumors